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Escape from the antiproliferative effect of transforming growth fac-
tor-1J1 in LLC-PK1 renal epithelial cells. Transforming growth factor-l3
(TGF-/31) usually inhibits proliferation of epithelial cells. We find that
LLC-PK, renal tubular epithelial cells develop rapid in vitro resistance
to the inhibitory effects of TGF-/31 and subsequently proliferate in
response to TGF-/31. This unique response to TGF-131 is not observed in
another renal tubular epithelial cell line (MDCK cells). The proliferative
response to TGF-/31 is additive to that produced by other growth
factors. The proliferative response to TGF-/31 occurs despite an effect
of TGF-/31 to suppress epidermal growth factor stimulated c-myc
mRNA as determined by Northern analyses. These results suggest that
LLC-PK1 cells develop rapid resistance to TGF-/31 inhibition of prolif-
eration in vitro and that this resistance occurs despite continued
suppression of c-myc mRNA.
Transforming growth factor-1 (TGF-/31) is a 25 kD dimeric
protein that belongs to a family of closely related peptides [1—3].
The TGF-j3s exert numerous effects on growth and differentia-
tion in multiple cell types [1, 2]. Most cells have receptors for
TGF-/3s and these peptides are felt to regulate cell function by
acting as paracine and autocrine systems [1—3]. Initially,
TGF-/3s were found to stimulate anchorage-independent growth
of fibroblasts in soft agar [4]. Later studies revealed that
TGF-p1 often inhibits the proliferation of numerous cell types
[1]. The mechanism(s) whereby TGF-/3 exert(s) this antiprolif-
erative effect remains unclear. However, several studies find
that the growth inhibitory properties of TGF-f3, occur in parallel
with inhibition of transcription of the c-myc oncogene [5—15]. A
role for the retinoblastoma tumor suppressor gene product
(pRB) in mediating TGF-/31 suppression of c-myc transcription
has been demonstrated in some studies [10, 12, 16]. More
recently, an effect of TGF-f31 to prevent progression of the cell
cycle beyond the G1 phase has been attributed to inhibition of a
cyclin-dependent kinase [17]. This inhibition correlated with
diminished phosphorylation of pRB [17].
Recently, we investigated the effects of several putative renal
epithelial cell growth regulators on signal transduction path-
ways in cultured renal cells [18]. To our surprise, we found that
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LLC-PK1 pig kidney epithelial cells develop rapid in vitro
resistance to the antiproliferative effect of TGF-/31. The present
studies were designed to characterize the response of LLC-PK1
cells to prolonged in vitro exposure to TGF-. Our results
demonstrated that initially TGF-131 inhibits 3H-thymidine up-
take and proliferation in LLC-PK1 cells. However, after 18
hours exposure, TGF-f31 no longer inhibits and in fact signifi-
cantly stimulates 3H-thymidine uptake and proliferation. Sev-
eral experiments were carried out to characterize the mecha-




Human recombinant TGF-/31 and TGF-a were obtained from
Rand D Systems. Phorbol 12-myristate 13-acetate was obtained
from Sigma. Human recombinant epidermal growth factor
(EGF) and insulin-like growth factors 1 and 2 (ILGF-1 and
ILGF-2 respectively) were obtained from UBI. Nitrocellulose
membranes were obtained from Schleicher and Schuell.
Cell culture
LLC-PK1 and MDCK cells were obtained from the American
Type Culture Collection. LLC-PK1 cells were grown in RPMI
medium and MDCK cells in MEM medium supplemented with
2.0 m glutamate. Both media were supplemented with 200
mg% sodium bicarbonate, 16 mr't Hepes, 100 Jml penicillin,
and 200 g/ml streptomycin. Newborn calf serum (6%) was
added to the media for the initial three to seven days of growth
after which all cultures received serum-free media. Serum-free
conditions were used for 48 hours prior to each experiment. The
cultures were maintained at 37°C in a humidified atmosphere of
95% air and 5% CO2. Cell growth was monitored under an
inverted microscope with phase optics (Nikon 1M35) and typi-
cally reached confluence in five to seven days.
3H-thymidine uptake and cell-counting studies
These studies were performed in 24-well panels in which cells
were growth to approximately 70 to 80% confluence. After
exposure to various effectors, media was replaced with fresh
media containing [methyl-3H]-thymidine (70 to 85 Ci mmol,
Amersham, 5 1.dlml media) with or without 6% newborn calf
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serum for four hours. Monolayers were then washed three
times with cold PBS, three times with cold 5% TCA and cells
solubilized in equal parts 0.25 N NaOH and 0.1% SDS. Radio-
activity was determined by liquid scintillation counting. For
each experiment, three to four wells were studied under each
experimental condition and the three to four results meaned to
obtain an N of one for that condition. Each experiment was
typically repeated on three to five occasions. In all experiments,
control cells were handled identically to experimental cells.
When cell counts were done, cells were washed three times
with PBS and removed from the dish with trypsin-EDTA (1:25
or 0.5 g trypsin and 0.2 g EDTA Na per liter), diluted in
serum-free media and counted on a hemocytorneter.
Northern blot analyses
For each experiment, 4 to 5 x 106 cells from a single 100 mm
plate were used for each study condition. In all studies,
poly(AY-RNA from cells was extracted using the Fast Track
mRNA Isolation Kit (Invitrogen, San Diego, California, version
1.1). Approximately, 2 to 4 g of poly(A)-RNA was electro-
phoresed through a 1.0% agarose gel with 2.2 M formaldehyde.
RNA was transferred to nylon membrane overnight (Nytran,
Schleicher and Schuell, Keene, New Hampshire, USA) by
capillary action. RNA was fixed to the membrane by short-
wave UV cross-linking (UV Stratalinker, Stratagene, La Jolla,
California, USA). Prehybridization was performed at 42°C for
two hours using a buffer composed of 5 x SSPE (SSPE contains
149 m NaCl, 10 mi NaH2PO4, 1 mri EDTA), 5x Denhardt's
solution (lx contains 0.1 g Ficoll, 0.1 g polyvinylpyrrolidone,
0.1 g bovine serum albumin and H20 to 500 ml), 0.1% sodium
dodecyl sulfate (SDS), 100 to 200 tg/ml of sheared, denatured
salmon sperm and 50% formamide (vol/vol). In more recent
experiments, another prehybridization buffer was used contain-
ing lOx SSPE, 50x Denhardt's, 10.0% SDS, 200 to 300 g/ml of
sheared, denatured salmon sperm, 40% formamide (vol/vol),
and 20% dextran sulfate (500,000 MS). Hybridization was
conducted for 12 to 24 hours at 42°C using either a commercially
available cDNA probe or a cDNA insert separated from its
plasmid in low-melt agarose. The probes were labeled with
about 5 pCi of [32P1-dATP (3000 Ci/mol, ICN) using random
primers. The eDNA probes used were a 2.0 kb fragment
representing the chicken f3-actin mRNA (Oncor) and a 2.3 kb
Barn Hi fragment containing exons 1, 2 and 3 of the mouse
c-myc gene (gift of Michael Cole). Hybridization was performed
in prehybridization buffer containing 1 x 106 cpm/ml of [32P1-
labeled cDNA probes. After hybridization, membranes were
washed twice for 15 minutes in 6x SSPE/0.l% SDS at room
temperature and twice for 15 minutes in lx SSPE/0. 1% SDS at
37°C. The membranes were then autoradiographed with inten-
sifying screens at —70°C for 24 to 96 hours. Blots were stripped
with 50% formamide/6x SSPE at 65°C for 30 minutes followed
by rinsing in 2x SSPE. After stripping, blots were subsequently
rehybridized with other probes as described above. All exper-
iments were repeated five times and representative autoradio-
graphs are shown. A Bio-Rad model 620 densitometer using l-D
analyst ii data analysis software (version 3.1) was used to
obtain relative values for mRNA expression. For mRNA anal-
yses, densitometric values for c-myc were divided by the
corresponding value for /3-actin. The values of these ratios from
individual experiments were then averaged.
Western blot analyses
Whole cell lysates were made by removing cells from the
culture dish with trypsin/EDTA. Cells were washed in PBS,
then PBS with 5 m MgC12 and then suspended in a hypotonic
lysis buffer containing DNase I (100 jig/mi), RNase A (50
jig/mi), pepstatin (10 jig/mi), leupeptin (10 jig/mi), PMSF (I
mM), MgCl2 (50 mM) and Tris 5.0 m. The suspension was
treated with 2.5% SDS and 100 msi DTT. Seventy-five micro-
grams of whole cell lysate were separated on denaturing SDS-
polyacrylamide gels. The separated proteins were transferred to
a nitrocellulose membrane in a Hoefer Scientific Transphor
apparatus at 4°C. After marking the position of the lanes, the
filter was immersed in lx PBS containing 5% non-fat milk
powder and 0.2% Tween 20. The filter was incubated with
gentle shaking at room temperature for one hour and washed
three times (10 mm) with lx PBS containing 0,05% Tween 20.
The filter was then incubated with various antibodies. The
antibodies used included an IgG2 monoclonal antibody that
recognizes an epitope near the C-terminal domain of p342
(Pharmingen) and a monoclonal antibody raised against a trp
E-Rb fusion protein (PMG 245, gift from WenHwa Lee, Uni-
versity of Texas Medical Center at San Antonio). After incu-
bation for 4 to 24 hours with the antibody, filters were washed
three times (10 mm) with lx PBS containing 0.05% Tween 20.
For studies utilizing pRB antibody, filters were then incubated
for 30 minutes with a rabbit anti-mouse secondary antibody and
washed three times as described above. The filters were then
incubated (30 mm) with a goat anti-rabbit horseradish peroxi-
dase conjugated antibody, washed as described, and immersed
for one minute in ECL luminol (Amersham). Filters were
rapidly dried and exposed to Kodak XAR film for 30 to 90
seconds. When the antibody directed against p342 was used,
after incubation with the antibody, the filter was washed as
described then incubated with about 0.5 mCi '251-labeled pro-
tein A (Amersham) in lx PBS containing 0.05% Tween for one
hour. The filter was then washed as described and exposed to
film overnight at —70°C between intensifying screens.
Protein assay
Protein was estimated by modified Bradford method (Bio-
Rad) using bovine serum albumin as a standard.
Statistical analyses
All calculations and analyses were carried out using an AU
PC-6300 desktop computer and ABSTAT software. All data
were expressed as the mean SEM. Statistical analyses were
performed using paired and unpaired Student's t-test and
ANOVA where appropriate. A P value of < 0.05 was consid-
ered significant.
Results
We first examined the effect of several putative growth
factors on LLC-PK1 [3H]-thymidine uptake. The effects of 24
hours exposure of LLC-PK1 cells to various concentrations of
these growth factors are depicted in Figure 1. Nearly identical
responses were observed when cells were given the growth
factors with or without concomitant 6% fetal calf serum. In
these studies, the phorbol ester phorbol 12-myristate 13-acetate
(PMA) and TGF-a both stimulated [3H]-thymidine uptake in a
dose-dependent fashion. To our surprise, TGF-/31 also modestly
stimulated [3H1-thymidine uptake while ILGF- 1 and ILGF-2
exhibited limited ability to promote [3H]-thymidine incorpora-
tion.
Proliferative responses to TGF-f31 are exceptionally unusual
in well-differentiated epithelial cells. Therefore, additional stud-
ies were undertaken. First, we examined the time course of
i0 M TGF-/31 on [1H]-thymidine uptake in LLC-PK1 cells
(Fig. 2). A biphasic pattern was observed with inhibition of
uptake observed after 6 and 12 hours exposure to TGF-f31
followed by modest stimulation of uptake after 18, 24 and 48
hours exposure. Removal of TGF-/31 from the media after 24
hours exposure was associated with a further modest increase
in [3H]-thymidine uptake when compared with cells that con-
tinued to be exposed to TGF-J31. To determine if this pattern of
response was unique for LLC-PK1 cells, another renal epithe-
hal cell line was studied (Fig. 2). In contrast to LLC-PK1 cells,
MDCK cells did not escape from the anti-proliferative effect of
TGF-/31 over 48 hours. The data depicted in Figure 2 were
performed in cells that were maintained serum-free for 48
hours. At time 0, both 6% calf serum l0— M TGF-/31 were
added for the indicated time periods.
Next, the effect of exposure for 24 hours to l0 M of
TGF-/31, EGF and TGF-a when given alone and together on
[3H]-thymidine uptake was examined (Fig. 3). As expected,
TGF-a and EGF modestly stimulated [3H1-thymidine uptake
and these effects were not additive. The effect of TGF-/31 to
stimulate [3H]-thymidine uptake in LLC-PK1 cells, however,
appeared to be, at least in part, additive to the effects of TGF-a
and EGF. By contrast, in MDCK cells, TGF-p1 pre-treatment
converted stimulatory effects of EGF and TGF-c on [3H]-
thymidine uptake into inhibitory effects as reported in other cell
lines [191. To determine if TGF-/31 affects LLC-PK1 cell num-
ber, a hemocytometer was used to count control cells and cells
treated for 12 to 15 and for 24 to 72 hours with TGF-p1. In these
studies, counts of cells treated with TGF-/31 for 12 to 15 hours
Fig. 2. Time course of effect of TGF-f31 (1O- M) on [3H1-thymidine
uptake in LLC-PK1 (0) and MDCK (•) cells. Interrupted line is from 24
to 48 hours represent cultures that had TGF-/31 removed. The data
represent the mean values of 4 experiments. The SEM for each time
point was less than 0.15-fold.
averaged 79 2% of control (untreated) values while counts of
cells treated with TGF-131 for 24 to 72 hours were 125 4% of
control. Together, these observations suggest that LLC-PK1
cells exhibit a unique response to TGF-/31 treatment causing
initial growth inhibition followed by stimulation of proliferation.
Moreover, the response to TGF-f31 to stimulate [3H]-thymidine
uptake in LLC-PK1 cells appears, at least in part, additive to
that of TGF-a and EGF.
The response of TGF-J31 exposed LLC-PK1 cells to escape
from growth suppression and to proliferate in response to
TGF-j31 could be explained by production of an overriding
growth factor. To study this possibility, the effects of media
removed from LLC-PK1 cells treated for 48 hours with l0 M
TGF-J31 and of media removed from control LLC-PK1 cells not
treated with TGF-f31 but observed over an identical 48 hour
period on [3H]-thymidine uptake were compared. In these
studies, after eight hours exposure to either the conditioned or
the control media, [3H]-thymidine was added to the media and
the cells harvested four hours later. The uptake of [3H]-
thymidine in LLC-PK1 cells exposed to the conditioned media
was less than in cells exposed to control media (8,460 285 vs.
10,371 315 cpm, respectively, N = 6, P < 0.05). This 18%
inhibition of [3H]-thymidine uptake produced by conditioned
media containing TGF-J31 at l0— M was nearly identical to that
observed (20 3%) with LLC-PK cells exposed to l0— M
TGF-/31 for 12 hours in non-conditioned media. In additional
studies, conditional media was concentrated four- to sixfold. In
these studies, [3H]-thymidine uptake in LLC-PK1 cells exposed
to the concentrated, conditioned media containing TGF-f31
exceeded that in cells exposed to concentrated, control media
(13,609 872 vs. 12,000 386 cpm, respectively; N = 8, NS).







Fig. 1. Effect of 24 hours exposure to several putative renal growth
factors on LLC-PK1 cell 13H1-thymidine uptake. The data represent the
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Fig. 4. Northern blots of c-myc (upper panels) and /3-actin (lower panels) mRNA after 2 hours (left four panels) and 24 hours (right four panels)
exposure to TGF-/3, in LLC-PK1 cells. First lane of each panel represents control, second lane 6 hours exposure to EGF (10_8 M), third lane TGF-f31(l0 Ni) and fourth lane TGF-/3, (l0 M) plus EGF (10-8 M). All studies were performed concurrently.
Studies in multiple cell types suggest that the anti-prolifera-
tive effect of TGF-/31 is associated with decreased expression of
the c-myc proto-oncogene [5—15]. We therefore studied North-
ern blots for c-myc mRNA isolated from LLC-PK1 and MDCK
cells exposed to EGF in the presence and absence of pretreat-
ment with TGF-/31. The effect of short-term (6 hr) exposure to
i0 M TGF-p1 on 108 M EGF-stimulated c-myc expression
was first examined (Fig. 4). When the ratio of c-myc to f3-actin
signal was meaned for five experiments, TGF-131 modestly
decreased EGF-stimulated c-myc expression in both LLC-PK1
(40 8%) and MDCK (35 5%) cells. Next, the effect of longer
(18 to 24 hr) exposure to TGF-/31 was examined (Fig. 5). In the
experiments (N = 5), TGF-f31 decreased the effect of exposure
to EGF to stimulate c-myc expression by 30 8% in LLC-PK1
cells and by 38 7% in MDCK cells. These results demonstrate
that TGF-/31 comparably inhibits EGF-stimulated c-myc ex-
pression in cells that escape (LLC-PK1) and do not escape
(MDCK) from TGF-/31 inhibition of proliferation as well as at
time points when TGF-131 treated LLC-PK1 cells exhibit inhi-
bition (6 hr) as well as stimulation (18 to 24 hr) of [3H]-
thymidine uptake.
We next undertook preliminary studies to clarify possible
mechanism whereby brief (less than 12 hr) exposure to TGF-f31
inhibits LLC-PK1 proliferation. Since the product of the reti-
noblastoma tumor suppressor gene has been implicated in
regulation of TGF-f31 inhibition of proliferation and suppression
of c-myc transcription [10—13, 16], we probed whole cell lysates
of LLC-PK1 cells with an antibody directed against pRB. The
results (Fig. 6) suggest that TGF-f31 pretreatment may decrease
steady-state expression of pRB. However, exposure to EGF
appears to increase pRB expression in both the absence of
presence of TGF-/31. We also utilized Western blots of whole
cell lysates to examine if the expression of p342, a cell cycle
protein that may be involved in proliferation, is affected by






Fig. 3. Effect of TGF-cs (10-8 M, ), EGF
(10_s M, ) and TGF-f3, (10 M, Ill) alone
and together [() TGF-a + EGF; () TGF-a
+ TGF-j3; (il) EGF + TGF-f3J on f3HJ-
thymidine uptake in MDCK cells (6 bars on
left) and LLC-PK1 cells (6 bars on right). The
values represent the mean SEM of 5
experiments. The noted growth factors and
6% calf serum were added simultaneously to
cells that were serum free for 48 hours prior
to study.
2Hrs 24Hrs
2.3 kb- a e I A c-myc
ease2.0 kb- a' -actin





646 Anderson et a!: Escape from TGF-j31 in renal cells
Fig. 5. Northern blots of c-myc (upper panels) and /3-actin (lower panels) mRNA after 2 hours (left panels) and 24 hours (right panels) exposure
to TGF-f31 in MDCK cells. First lane of each panel represents control, second lane 6 hours exposure to EGF (10-8 M), third lane TGF-f1 (l0
M) and fourth lane TGF-/31 (l0 M) plus EGF (108 M).
Fig. 6. Western blot of LLC-PK, cell lysates
probed with an antibody directed against
retinoblastoma protein. The first lane is
control, second lane 2 hours exposure to EGF
(108 M), third lane 6 hours exposure to EGF,
fourth lane TGF-131 (10 M) for 2 hours
preceding 2 hours exposure to EGF (10-8 M)
and sixth lane TGF-j31 (10-s M) for 2 hours
preceding 6 hours exposure to EGF (l0- M).
EGF and TGF-p1. Western blots probed with an antibody
directed against a carboxy terminal epitope of p34cc2 did not
demonstrate a major effect of TGF-131 to alter EGF-stimulated
steady state expression of p34cdc2 (Fig, 7).
Discussion
TGF-/31 is of interest with regard to the kidney because it has
been shown to be an important regulator of renal tubular and
glomerular mesangial and epithelial cell proliferation [19—22].
Moreover, TGF-/31 may regulate renal epithelial cell production
of extracellular matrix, facilitate intercellular communication
and modulate cell phenotype [19, 23, 24]. Transforming growth
factor /3 also may be a pathogenetic regulator in renal response
to a variety of insults including glomerulonephntis [25, 261,
obstructive uropathy [27] and diabetes mellitus [28, 29]. The
present studies were therefore undertaken to gain a better
understanding of the mechanisms whereby TGF-/31 regulates
renal tubular epithelial cell proliferation.
The major finding of the present study is that a well-differen-
tiated pig kidney epithelial cell line (LLC-PK1 cells) exhibits
unique responses to TGF-/31. Initially, TGF-p1 inhibits [3H]-
thymidine uptake and proliferation. This inhibition lasts for
Fig. 7. Western blot of LLC-PK, lysates
probed with an antibody directed against a
portion of the p342 protein. The conditions
of lanes I through 6 are identical to the
conditions for lanes 1 through 6 described in
the legend to Figure 6.
about 12 to 18 hours and is followed by stimulation of [3H}-
thymidine uptake and proliferation. The stimulation of [3H]-
thymidine uptake following 24 hours exposure to TGF-f31 is, at
least in part, additive to that produced by TGF-a and EGF. This
biphasic response of LLC-PK1 cells to TGF-/31 is not a special
characteristic of renal tubular epithelial cells since TGF-f31
persistently inhibits basal, TGF-a- and EGF-stimulated [3H]-
thymidine uptake in another renal tubular epithelial cell line
(MDCK cells). TGF-f3 inhibits [3H]-thymidine uptake in the
vast majority of well-differentiated epithelial cells in which it
has been studied [1—17, 19]. Resistance to TGF-J3-induced
proliferation has been reported to occur very rarely (<0.01%) in
well-differentiated human colon cancer cells and only tran-
siently in MvlLu mink lung epithelial cells despite exposure to
TGF-/31 for several days [8, 29]. Resistance to TGF-/3 inhibition
of cell growth is more commonly observed in human cancer
cells including those of retinoblastoma, colon, breast, cervical,
bladder and skin origin [29—35]. Also, chemical mutagenesis as
well as introduction of the E1A and v-rafoncogenes can result
in resistance to TGF-13 inhibition of growth [35, 36]. Although
these transformed cells can develop resistance to TGF-/31, a
proliferative response as observed in the present studies has
been found only in fibroblasts grown in an anchorage indepen-
dent mode [4].
Two potential explanations for the development of resistance
to TGF-/31 growth inhibition include either neutralization of
TGF-f3 or production of an overriding growth factor. With
regard to possible neutralization of TGF-f31, in some cell types
TGF-f31 induces production of the proteoglycan decorin which
binds TGF-/31 thereby preventing access to its receptor [39].
With regard to an overriding growth factor, in mesangial cells
TGF-/31 can induce genes for the platelet-derived growth factor
[20]. The observations of the present study that concentrated
conditioned media from TGF-f3 exposed cells no longer inhibit
[3H]-thymidine uptake may support the presence of either an
overriding growth factor or a TGF-f3 inhibitor. However, our
conditioned media experiments are not definitive and further
studies are required to resolve this issue.
It is also possible that TGF-f3 resistance could be explained
by a change in TGF-j3 receptor type and/or characteristics. For
example, malignant and chemically mutagenized cells that are
resistant to TGF-131 lose TGF-/31 binding ability [34, 36, 40]. In
those cell lines that are resistant to TGF-f31, restoration of
either both type I and type II or only type II TGF-/3 receptors
by hybridization techniques restores TGF-f31 inhibition of pro-
liferation [29, 34, 40]. However, loss of TGF-j3 receptors does
not readily explain the TGF-f31 enhancement of [3H]-thymidine
uptake that we observed. We also found that at a time at which
LLC-PK1 cells have escaped from the anti-proliferative effect
of TGF-/31, TGF-/31 treated cells continue to exhibit suppres-
sion of EGF stimulated c-myc expression suggesting the pres-
ence of a functional TGF-p1 receptor linked to one of the known
TGF-f3 post-receptor signaling pathways. Although studies of
TGF-f31 receptors are clearly needed to clarify our observa-
tions, some of our results suggest that post-receptor events
contribute, at least in part, to the TGF-p resistance that we
observed.
The post-receptor signaling pathways involved in TGF-f31
biological effects have not been totally clarified. Our previous
investigations suggest that cyclic AMP and protein kinase A
may be involved [18]. In other studies, a consistent observation
has been that TGF-p1 inhibition of proliferation occurs in
parallel with suppression of basal and growth factor-stimulated
transcription of the c-myc oncogene, an oncogene which is
2
Anderson et al: Escape from TGF-/3, in renal cells 647
3 4 5 6
a
44-
648 Anderson et al: Escape from TGF-f31 in renal cells
associated with cell proliferation [8—15]. For example, cells that
are resistant to the growth inhibitory properties of TGF-/31 do
not exhibit decreased c-myc expression following TGF-/31 [8,
30]. The precise mechanism(s) whereby TGF-/31 leads to sup-
pression of c-myc expression remains unclear. Most [10—12] but
not all studies [13] suggest that the product of the retinoblas-
toma tumor suppressor gene (pRB) plays a critical role in
mediating TGF-f3 suppression of c-myc transcription. We there-
fore examined EGF-stimulated c-myc expression in the present
studies. Our results demonstrate that escape from TGF-f31
growth inhibition in LLC-PK1 cells occurs despite continued
modest suppression of c-myc expression as determined by
Northern analyses. Further studies are needed to determine the
mechanism of this decrease in c-myc expression. We also used
Western blots to examine the short-term effects of EGF and
TGF-/31 (alone and together) on LLC-PK1 expression of pRB.
These results suggest that EGF may increase and TGF-f31
decrease steady state expression of pRB. Clearly, more studies
are also needed to clarify the relationship between TFG-/31,
EGF and pRB in LLC-PK1 cells.
Recently, a post-translational relationship between pRB and
c-myc protein has also been found [41, 42]. These two proteins
can physically bind to each other [32] and microinjection
studies suggest that these proteins antagonize the growth effects
of one another within the cell [421. These observations are of
particular interest with regard to TGF-/31 resistance in view of
the recent findings of Missero and colleagues [37, 38]. In these
studies, TGF-/31 resistance occurs in keratinocytes transformed
with the E1A oncogene. This resistance correlates closely with
the ability of EIA proteins to bind pRB and three other cellular
proteins including a cdc3-associated cell-cycle regulatory pro-
tein [37]. Binding of E1A to subsets of these four proteins
induced only partial resistance to TGF-/31 [37]. More recently,
Koff and coworkers found that TGF-/3 inhibition of proliferation
in MvlLu cells was associated with failure to assemble func-
tional cyclin and cyclin dependent kinases and these effects
correlated with decreased pRB phosphorylation [17]. In the
present studies, we did not find an effect of either EGF TGF-p1
to regulate steady-state expression of a p34 kinase. It is clear
that further studies examining the role of pRB, cyclin and
cyclin-dependent kinases are required to clarify the mecha-
nisms of the escape from TGF-/31 inhibition of growth that we
observed in LLC-PK1 cells.
In summary, the present results find that LLC-PK1 renal
epithelial cells develop rapid, in vitro resistance to the growth
inhibitory properties of TGF-/31. This unique response to
TGF-f31 in LLC-PK1 renal tubular epithelial cells is not seen in
another renal epithelial cell line (MDCK cells). The prolifera-
tive response to TGF-f31 in LLC-PK1 cells is additive to that of
other growth factors and occurs despite the continued effect of
TGF-/31 to suppress EGF-stimulated c-myc expression. The
ability of LLC-PK1 renal epithelial cells to escape from TGF-f3
growth inhibition provides an excellent opportunity to delineate
the mechanism(s) whereby TGF-/3 and other growth factors
exert their effects on renal tubular epithelial cell growth. In
particular, further studies to delineate the possible role of
reduced pRB expression and other cellular factors in these
unique LLC-PK1 responses to TGF-j31 will be of great interest.
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